Med-Chemist

Med-Chemist : "Quintessential Medicinal Chemistry"

Showing posts with label Nilotinib. Show all posts
Showing posts with label Nilotinib. Show all posts
Thursday, June 21, 2018

Novartis Drug Tasigna Approved by FDA to Treat Children with Rare Form of Leukemia

›
In continuation of my update on Nilotinib Novartis announced today that the US Food and Drug Administration (FDA) expanded t...
Thursday, February 1, 2018

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

›
In continuation of my update on nilotinib Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusi...
Monday, April 17, 2017

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

›
My updates on   nilotinib A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly...
Thursday, December 17, 2009

Nilotinib more efficiant over Imatinib for (Ph+ CML)....

›
Nilotinib ( see structure ) : Nilotinib , in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor, approved as Ta...
›
Home
View web version

Contributors

  • Dr. Umesh..
  • https://www.med-chemist.com
Powered by Blogger.